These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24670186)

  • 1. Thrombotic microangiopathy associated with interferon beta.
    Hunt D; Kavanagh D; Drummond I; Weller B; Bellamy C; Overell J; Evans S; Jackson A; Chandran S
    N Engl J Med; 2014 Mar; 370(13):1270-1. PubMed ID: 24670186
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis.
    Mahe J; Meurette A; Moreau A; Vercel C; Jolliet P
    Drug Des Devel Ther; 2013; 7():723-8. PubMed ID: 23950639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-beta in multiple sclerosis causing thrombotic microangiopathy.
    Yam C; Fok A; Mclean C; Butler E; Kempster P
    Intern Med J; 2019 Feb; 49(2):274-276. PubMed ID: 30754081
    [No Abstract]   [Full Text] [Related]  

  • 4. Comment on thrombotic microangiopathy induced by interferon-β therapy.
    Cavoli GL; Passantino R; Tortorici C; Bono L; Ferrantelli A; Rotolo U
    Clin Nephrol; 2012 Dec; 78(6):506-7. PubMed ID: 23164420
    [No Abstract]   [Full Text] [Related]  

  • 5. Thrombotic microangiopathy induced by long-term interferon-β therapy for multiple sclerosis: a case report.
    Broughton A; Cosyns JP; Jadoul M
    Clin Nephrol; 2011 Nov; 76(5):396-400. PubMed ID: 22000560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interferon ß, nephrotic syndrome and thrombotic microangiopathy].
    Quintana LF; Campistol JM
    Med Clin (Barc); 2015 Jan; 144(2):65-6. PubMed ID: 25458512
    [No Abstract]   [Full Text] [Related]  

  • 7. Thrombotic microangiopathy due to acquired complement factor I deficiency in a male receiving interferon-beta treatment for multiple sclerosis.
    Mrabet S; Dahmane R; Raja B; Fradi A; Aicha NB; Sahtout W; Azzabi A; Guedri Y; Zellama D; Achour A; Sfar I; Goucha R; Abdessayed N; Mokni M
    Br J Clin Pharmacol; 2023 May; 89(5):1682-1685. PubMed ID: 36480744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of malignant hypertension with thrombotic microangiopathy.
    Zhang J; Hu Z
    Intern Med J; 2018 Mar; 48(3):361-362. PubMed ID: 29512323
    [No Abstract]   [Full Text] [Related]  

  • 9. Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report.
    Gerischer LM; Siebert E; Janke O; Jungehuelsing GJ; Ruprecht K
    Mult Scler Relat Disord; 2016 Nov; 10():63-65. PubMed ID: 27919500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant hypertension as a rare cause of thrombotic microangiopathy.
    Thind G; Kailasam K
    BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28596204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombotic Microangiopathy after a 15-year Treatment with Interferon Beta-1b in a Patient with Multiple Sclerosis: A Case Report and Review of Literature.
    Akita S; Fujibayashi K; Ueno EI; Wakasa M; Kawai Y; Kajinami K
    Intern Med; 2024 Apr; 63(8):1113-1117. PubMed ID: 37661454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon beta-1b.
    Goodkin DE
    Lancet; 1994 Oct; 344(8929):1057-60. PubMed ID: 7934448
    [No Abstract]   [Full Text] [Related]  

  • 13. Malignant hypertension and interferon-beta: a case report.
    Rubin S; Lacraz A; Galantine V; Gosse P
    J Hum Hypertens; 2014 May; 28(5):340-1. PubMed ID: 24067346
    [No Abstract]   [Full Text] [Related]  

  • 14. Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
    Evans R; Rudd P; Bass P; Harber M
    BMJ Case Rep; 2014 Feb; 2014():. PubMed ID: 24503666
    [No Abstract]   [Full Text] [Related]  

  • 15. Malignant Hypertension with Thrombotic Microangiopathy.
    Mitaka H; Yamada Y; Hamada O; Kosaka S; Fujiwara N; Miyakawa Y
    Intern Med; 2016; 55(16):2277-80. PubMed ID: 27523008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon treatment for multiple sclerosis: autoimmune complications may be lethal.
    Durelli L; Bongioanni MR; Ferrero B; Oggero A; Marzano A; Rizzetto M
    Neurology; 1998 Feb; 50(2):570-1. PubMed ID: 9484407
    [No Abstract]   [Full Text] [Related]  

  • 17. Liver injury associated with the beta-interferons for MS.
    Francis GS; Kaplowitz N; Alteri E
    Neurology; 2004 Sep; 63(6):1142-3; author reply 1142-3. PubMed ID: 15457586
    [No Abstract]   [Full Text] [Related]  

  • 18. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
    Knobler RL; Greenstein JI; Johnson KP; Lublin FD; Panitch HS; Conway K; Grant-Gorsen SV; Muldoon J; Marcus SG; Wallenberg JC
    J Interferon Res; 1993 Oct; 13(5):333-40. PubMed ID: 8301153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report.
    Kocer B; Nazliel B; Oztas M; Batur HZ
    Eur J Neurol; 2009 Apr; 16(4):e78-9. PubMed ID: 19222549
    [No Abstract]   [Full Text] [Related]  

  • 20. Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS.
    Río J; Montalban X
    Neurology; 2000 Apr; 54(8):1710. PubMed ID: 10762530
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.